1 / 14

Application of filamentous phages In nanobiotechnology

Application of filamentous phages In nanobiotechnology. 1) Peptide phage display: isolate binders of semiconductors.

tiger
Download Presentation

Application of filamentous phages In nanobiotechnology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Application of filamentous phages In nanobiotechnology

  2. 1) Peptide phage display: isolate binders of semiconductors Phage structure and phage display selection process. (a) Schematic diagram of phage and its genome and (b) phage-display process to identify specific binding peptide motifs against desired targets.

  3. 2) Use the isolated phages as nucleation centers for the fabrication of nanoparticles and nanowires

  4. Application of filamentous phages As nanomedicines Phages as vehicles for gene and vaccine delivery Phages as tool for imaging Phages as vehicles for gene and drug delivery

  5. Pasqualiny and Arap group Combine: 1) Gene delivery 2) Specific targeting 3) Imaging

  6. Drug Carrier Drug Targeting moiety Drug Specificity Affinity Chemical tolerance Labile linker High capacity biocompatibility Proper kinetics Temporal Spatial Components of a targeted drug carrying platform Potency

  7. XII g8 g3 g2 g10 g5 IG g6 g1 g9 g4 I - g8 protein - g6 protein - g3 protein - g7 protein - g9 protein The filamentous bacteriophage as a targeted drug-carrying nanomedicine 6nm 800-2000 nm (dependent on the size of the packaged genome) Scheme of the filamentous Fd phage. In out system, the minor coat protein, p3 (g3p) carries the targeting moiety which the drug, and the engineered release mechanism are on p8 (g8p).

  8. - ZZ domain - IgG fUSE5 - ZZ pCANTAB5-ZZ M13 KO7 IgG complexed to fUSE5-ZZ phage through a p3-displayed ZZ domain A B C fUSE5-ZZ phage used for targeting. A Scheme of the filamentous fUSE5-ZZ phage. B. Evaluationof ZZ domain display by an immunoblot. Phage particles (each lane is identified with the corresponding phage name below it)were separated by SDS/PAGE and electro-botted onto nitrocellulose, and the p3 minor coat protein or the derived ZZ domain-p3 fused derivative was detected with an anti-p3 antibody. The upper arrow marks the position of the ZZ-p3 fusion, while the lower arrow marks the position of the wild-type p3 coat protein. C. Evaluation of antibody binding capacity by competitive ELISA. 1012 fUSE5-ZZ phages were complexed with 0.6 mg (*3 dil) or 0.2 mg (*9 dil) of HRP-conjugated rabbit anti mouse IgG as tracer, in the presence of varying concentrations of protein-A purified human IgG. The residual HRP on the phages was detected using the substrate TMB.

  9. P8 coat protein monomer (of ~ 3000) Exposed amine residues : 2 DNA interacting zone

  10. Preparation of drug-linker adduct Chloramphenicol was modified in two steps to create an ester bond between CAM and a linker (originated in glutatic anhydride) The linker CAM complex is activated for lysine conjugation by the NHS procedure.

  11. Kinetics of drug release by serum esterases (here: 10% horse serum analysis by HPLC)

  12. Partial growth inhibition of staphylococcus aureus by antibody-targeted drug-carrying phages (3000 Cam/phage) Similar Partial growth inhibition was obtained by peptide-targeted phages

  13. The limitations: • Limited arming efficiency due to drug hydrophobicity • Solubility of the platform also affected • Vulnerability of the targeting moiety (ZZ domain) to amine chemistry

More Related